Blog
Published July 6, 2021
Executive Summary
The Chinese National Reimbursement Drug List (NRDL) is managed and negotiated by the National Healthcare Security Administration (NHSA) and drugs listed on the NRDL are reimbursed by the public insurance
Since 2017, on average, a significant price discount of 44-61% was required for products to achieve a positive listing on the NRDL
Based on average 2018 sales data, products included on the 2017 NRDL were able to achieve an increase in sales revenue (188%) despite the steep average…
Read Now
Blog
Published June 2, 2021
Executive Summary
The Medical Fund Bill would increase drug spending up to 4% of the total healthcare spending in Poland
The reimbursement applications can be reviewed as quickly as 180 days, reducing the typical time-to-market of two – three years
The criteria for “innovativeness” that need to be met for inclusion on the list are still not fully fleshed out to date
Only four of the 12 candidates on the list have been approved by the Health Minister to secure reimbursement…
Read Now
Case Studies
Trinity organized a full day on-site workshop to bring together key cross functional client teams to align on a final launch strategy for their mNSCLC asset in Japan.
Geographic Scope:
Client Situation:
The client wanted to build alignment on the launch pricing & market access assumptions for their asset in metastatic non-small cell lung cancer (mNSCLC) and metastatic colorectal cancer (mCRC) in Japan, including consideration of all forecasting assumptions and pricing and market access (P&MA) risks.
Trinity’s Solution:
Trinity conducted targeted secondary research to determine the existing mNSCLC…
Read Now
Blog
Published June 2, 2020
Executive Summary
China’s 2019 National Reimbursement Drug List (NRDL) update offers manufacturers key learnings and insights for future NRDL negotiations, particularly with respect to the negotiation tactics used in different disease areas; although in most disease areas the comparative negotiation rule was employed during the 2019 NRDL, the use of a new competitive negotiation rule employed in the hepatitis C disease area characterized the 2019 NRDL negotiations; under this rule, no base price was set and manufacturers were invited to…
Read Now
White Papers
By 2022 Europe is forecast to account for 20% of a global US$1.2 trillion pharmaceutical market. For executives from emerging biopharmaceutical companies planning to develop and commercialize their assets in Europe, the views of biopharmaceutical investors are critical, as investors provide the necessary investments. Additionally, investors who have analyzed numerous biopharmaceutical companies will have valuable experience on what drives commercial success.
In this paper, we aim to understand the views of both investors and biopharmaceutical companies, specifically on the investments…
Read Now